Comparing the current results to its competitors, Werewolf Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Werewolf Therapeutics Inc 's competitors' average revenue growth of 2.85 %, achieved in the same quarter.
Werewolf Therapeutics Inc 's Comment on Competition and Industry Peers
The company faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions. Competitors are developing cancer immunotherapies using modalities such as monoclonal antibodies, cell therapies, oncolytic viruses, and vaccines. The company's lead product candidate, WTX-124, may compete with other IL-2 based cancer therapies, including Proleukin (aldesleukin), which is approved for metastatic renal cell carcinoma and metastatic melanoma. Competitors often have greater financial resources and expertise in research, development, clinical trials, manufacturing, and marketing. Industry consolidation through collaborations, mergers, and acquisitions may concentrate resources among fewer competitors, while smaller or early-stage companies may also compete through partnerships with larger companies.
April 23, 2024
In a groundbreaking presentation at the AAI Annual Meeting, Werewolf Therapeutics unveiled their pioneering research, highlighting the immense potential of IL-10 INDUKINE molecules as a promising therapy for the treatment of inflammatory bowel disease (IBD). Drawing upon the transformative capabilities of their revolutionary PREDATOR platform, the scientific community witnessed the first preclinical data demonstrating the unprecedented potential for this novel therapeutic approach.IBD, a chronic inflammatory disorder of the gastrointestinal tract, encompasses two major forms, Crohn s disease and ulcerative colitis. These debilitating conditions affect millions globally, causing persistent inflammation, excru...
Publicly Traded Peers of Werewolf Therapeutics Inc
Repare Therapeutics Inc Share Performance
+35.20%
This Quarter
Repare Therapeutics Inc
Profile
Repare Therapeutics Inc is a biotechnology company that specializes in the development of precision oncology drugs. Their business model focuses on leveraging synthetic lethality, a targeted therapy approach, to identify and develop small molecule drugs for the treatment of various forms of cancer. By discovering and advancing novel therapeutics, Repare Therapeutics aims to improve patient outcomes and address unmet medical needs in oncology.
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.
Allakos Inc's business model revolves around developing and commercializing innovative therapeutic antibodies to treat allergic and inflammatory diseases.
Sources:
Werewolf Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Werewolf Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
